After years of struggling to get a positive readout for its cancer immunotherapy candidate tremelimumab, AstraZeneca is in a hurry to get it approved and on the market, and could achieve that goal before the end of 2022 thanks to the use of a priority review voucher.
A biologics license application for tremelimumab has been accepted for priority review by the US Food and Drug Administration for...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
